Finasteride


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0003993 Acid phosphatase activity Decreases phenotype PMID:33003968
GO:0004035 Alkaline phosphatase activity Decreases phenotype PMID:33003968
GO:0004364 Glutathione transferase activity Decreases phenotype PMID:33003968
GO:0004457 Lactate dehydrogenase activity Increases phenotype PMID:33003968
GO:0004784 Superoxide dismutase activity Decreases phenotype PMID:33003968
GO:0006641 Triglyceride metabolic process Affects phenotype PMID:39265715
GO:0006702 Androgen biosynthetic process Decreases phenotype PMID:11118046
GO:0006749 Glutathione metabolic process Affects phenotype PMID:27866977; PMID:33003968; PMID:38216069
GO:0006915 Apoptotic process Increases phenotype PMID:39265715
GO:0007283 Spermatogenesis Affects phenotype PMID:33003968; PMID:38216069
GO:0008283 Cell population proliferation Decreases phenotype PMID:7855976
GO:0008284 Positive regulation of cell population proliferation Affects phenotype PMID:11118046
GO:0014806 Smooth muscle hyperplasia Increases phenotype PMID:31454150
GO:0019852 L-ascorbic acid metabolic process Affects phenotype PMID:33003968
GO:0030539 Male genitalia development Decreases phenotype PMID:30768126
GO:0034440 Lipid oxidation Increases phenotype PMID:27866977; PMID:33003968; PMID:38216069; PMID:39265715
GO:0045429 Positive regulation of nitric oxide biosynthetic process Increases phenotype PMID:27866977
GO:0045454 Cell redox homeostasis Decreases phenotype PMID:27866977
GO:0046660 Female sex differentiation Increases phenotype PMID:1324152
GO:0046661 Male sex differentiation Decreases phenotype PMID:1324152
GO:0047823 D-glutamyltransferase activity Increases phenotype PMID:33003968
GO:0048808 Male genitalia morphogenesis Decreases phenotype PMID:1324152
GO:0050996 Positive regulation of lipid catabolic process Increases phenotype PMID:36015278
GO:0060009 Sertoli cell development Affects phenotype PMID:38216069
GO:0060161 Positive regulation of dopamine receptor signaling pathway Decreases phenotype PMID:27750143
GO:0060512 Prostate gland morphogenesis Decreases phenotype PMID:1324152
GO:0061107 Seminal vesicle development Decreases phenotype PMID:1324152
GO:0061370 Testosterone biosynthetic process Increases phenotype PMID:11118046; PMID:31454150; PMID:39265715
GO:0070994 Detection of oxidative stress Increases phenotype PMID:39265715
GO:0097722 Sperm motility Decreases phenotype PMID:33003968; PMID:38216069
GO:1901671 Positive regulation of superoxide dismutase activity Decreases phenotype PMID:27866977
GO:1903284 Positive regulation of glutathione peroxidase activity Decreases phenotype PMID:27866977
GO:1903409 Reactive oxygen species biosynthetic process Increases phenotype PMID:24136188
GO:1903787 Negative regulation of glutathione biosynthetic process Increases phenotype PMID:36015278
GO:2000845 Positive regulation of testosterone secretion Increases phenotype PMID:11118046
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.